Half of Novo Nordisk's Wegovy business now comes through out-of-pocket, self-pay channels, a company executive said Monday, and direct cash purchases make up 90% of demand for the Wegovy pill, Reuters reported. The disclosure came at the drugmaker's capital markets day in London, where executives described a pivot toward a more consumer-facing business model.
For many households, the figure reflects a hard reality. Instead of an insurance copay, many people are paying hundreds of dollars a month directly to stay on a weight-loss drug. Cash prices are far lower than list prices, but they still add up to thousands of dollars a year for a medication many patients take long term.
The disclosure comes as employers finalize 2027 benefits ahead of open enrollment, when families learn whether their plan will cover GLP-1 drugs next year.
A Company Under Pressure
Novo is under pressure from investors and from rival Eli Lilly, whose Zepbound is on track to outsell Wegovy by more than $7 billion this year, according to LSEG data cited by Reuters. Novo shares slid as much as 9% during Monday's event before recovering some of those losses.
Chief Executive Mike Doustdar said the oral Wegovy pill has reached 7 million U.S. prescriptions to date. The company said staff departures from its cost-cutting drive have reached 13,000, and analysts pressed executives on pricing ahead of the loss of patent protection for semaglutide, the active ingredient in Wegovy and Ozempic.
"They (also) did not say much in terms of how to tackle the semaglutide patent expiration in 2032," Markus Manns, a portfolio manager at Union Investment, told Reuters.
BMO analyst Evan Seigerman said in a note that the burden of proof now rests on management to show it can execute. Novo said it aims to reach more than 60 million patients worldwide by 2030 and plans to launch its CagriSema combination early next year.
The 50% self-pay figure is a company statement, not an independent audit, and Novo did not specify whether it refers to prescriptions, patients, or revenue. It also does not show how many people stopped treatment because they could not afford it.
The Real Monthly Cost for Households
Through Novo's NovoCare Pharmacy and savings program, new self-pay patients pay $199 a month for the first two monthly fills of the 0.25 mg and 0.5 mg starter doses, an offer that runs through December 31, 2026. After that, Wegovy injection doses up to 2.4 mg cost $349 a month, and the higher-dose Wegovy HD 7.2 mg injection costs $399. At $349 a month, a year of maintenance treatment costs about $4,188. Novo says its pricing will be updated after December 31, 2026.
The Wegovy pill is cheaper at lower doses. Novo lists $149 a month for the 1.5 mg dose, or about $1,788 a year, $199 a month for the 4 mg dose, and $299 a month for the 9 mg and 25 mg doses. Many insurers still exclude weight-loss drugs, which may help explain why nearly all pill demand is cash-based.
People with commercial insurance that covers Wegovy may pay as little as $25 a month with a manufacturer savings offer, subject to a maximum savings of $100 a month. That copay offer does not apply to government insurance, although government-insured patients can pay the self-pay price outside their coverage.
Coverage is shrinking in some states. In Massachusetts, commercial plans covered GLP-1 weight-loss drugs for 52% fewer residents after major insurers dropped routine coverage, MedicalDaily reported this week.
The families most exposed are adults with obesity but without diabetes, whose plans often exclude weight-loss drugs, and lower-income workers who cannot absorb several hundred dollars a month. Novo has said it will move to a unified list price of $675 across Ozempic, Wegovy, and Rybelsus in January 2027, MedicalDaily previously reported, a change that could affect employer coverage decisions again.
Medicare's $50 Option and Other Paths
Older adults have a separate route. The Medicare GLP-1 Bridge, which began July 1 and runs through December 31, 2027, lets eligible Part D enrollees get certain GLP-1 medications for $50 a month, according to CMS. Novo says the $50 price applies to adults with Medicare who are prescribed Wegovy for weight loss.
"These treatments are a major medical advancement, but too many seniors are currently unable to access them due to high cost," CMS Administrator Dr. Mehmet Oz said when announcing the program. Eligibility details are posted on the CMS program page.
For everyone else, a few steps can prevent surprises. Check your plan's summary of benefits during open enrollment to see whether GLP-1 drugs for weight loss are covered and whether prior authorization is required. Ask your prescriber whether a covered use, such as cardiovascular risk reduction, applies to you.
If you pay cash, compare the manufacturer's price with any pharmacy discount before filling. Compounded versions sold by some telehealth companies can cost less, but they are not FDA-approved products, and their quality can vary.
Do not stop or cut back a prescribed dose to stretch a supply without talking to a clinician. If price is the barrier, ask whether a lower-cost form or dose is appropriate. Some employer plans also attach conditions, such as enrollment in a weight-management program, so read the eligibility rules carefully. People who stop GLP-1 drugs often regain weight, and anyone using the medication for diabetes needs a plan to keep blood sugar controlled.
Employers and insurers will release 2027 plan details during fall open enrollment, and Novo's list price changes take effect in January. MedicalDaily will report on how the shift to cash pay affects coverage and access.
Key Questions Answered
What did Novo Nordisk announce? A company executive said self-pay channels now account for 50% of the Wegovy business and 90% of demand for the Wegovy pill.
How much does Wegovy cost without insurance? Through NovoCare, most injection doses cost $349 a month after two introductory fills at $199. The pill starts at $149 a month.
Can Medicare patients get Wegovy for less? Eligible Part D enrollees can get Wegovy for weight loss for $50 a month through the Medicare GLP-1 Bridge, which runs through 2027.
Does my commercial insurance cover it? It depends on your plan. Check your summary of benefits during open enrollment and ask about prior authorization.
Are compounded versions a safe substitute? Compounded semaglutide is not FDA-approved, and quality can vary. Talk with a clinician first.
Should I stop Wegovy if I cannot afford it? Talk with your prescriber before stopping. Weight regain is common, and people with diabetes need a plan for blood sugar control.
Published by Medicaldaily.com
